finance.yahoo.com ·
evolent health q1 earnings call 091228537
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEvolent Health's Q1 earnings show stable performance with new contract wins in specialty care (oncology, cardiology, advanced imaging). The company's revenue and EBITDA guidance reaffirmation indicates steady growth in the healthcare services sector. The medical expense ratio improvement suggests better cost management. Commercial mechanism: revenue expansion from new contracts (demand_spike for specialty care services) and margin improvement from operational efficiency. Impact is company-specific and sector-specific (healthcare services).
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Evolent Health Q1 2026 revenue $496M, adjusted EBITDA $22M, in line with expectations.
- Full-year revenue guidance reaffirmed at $2.4B-$2.6B, adjusted EBITDA $110M-$140M.
- New contract wins: advanced imaging deal covering 4.5M lives; national payer expansion in oncology and cardiology projected >$200M annual revenue.
- Medical expense ratio improved to 93%; management expects Q3 peak then improvement by year-end.